SCHEMBL2748263

SCHEMBL2748263

O=CNC(=O)Cc1cc(F)cc(F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
MAPK8 P45983 1/20 0.44
SIGMAR1 Q99720 1/20 0.40
GAA P10253 1/20 0.38
SMYD3 Q9H7B4 1/20 0.37
PSEN1 P49768 5/20 0.36
PSEN2 P49810 5/20 0.36
APH1B Q8WW43 5/20 0.36
NCSTN Q92542 5/20 0.36
APH1A Q96BI3 5/20 0.36
PSENEN Q9NZ42 5/20 0.36
GSK3B P49841 1/20 0.36
BACE1 P56817 1/20 0.36
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35
KCNQ3 O43525 1/20 0.35
KCNQ2 O43526 1/20 0.35
SRC P12931 1/20 0.35
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2748956 0.88 METAP2 (0.39) MEN1KMT2AMAPK8SIGMAR1BACE1
SCHEMBL964757 0.76 MAPK8 (0.50) MEN1KMT2AMAPK8SIGMAR1GAA
SCHEMBL13329774 0.76 KMT2A (0.53) MEN1KMT2AMAPK8SIGMAR1GAA
SCHEMBL6222073 0.74 MEN1 (0.39) MEN1KMT2AMAPK8SIGMAR1SMYD3
SCHEMBL21981007 0.73 MEN1 (0.50) MEN1KMT2AMAPK8SIGMAR1GAA
SCHEMBL2750185 0.72 MEN1 (0.61) MEN1KMT2AGAACES2CES1
SCHEMBL6863580 0.72 CES2 (0.46) MEN1KMT2AMAPK8SIGMAR1GSK3B
SCHEMBL24386385 0.72 KMT2A (0.45) MEN1KMT2AMAPK8SIGMAR1GAA
SCHEMBL21672231 0.72 KMT2A (0.53) MEN1KMT2AMAPK8SIGMAR1GAA
SCHEMBL14367227 0.72 ALDH1A1 (0.45) MEN1KMT2AMAPK8SIGMAR1PSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178668-B2 2-aminopyridine kinase inhibitors OSI Pharmaceuticals, LLC (US) 2012-05-15 US disclosed
EP-2265270-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2010-12-29 EP disclosed
WO-2009099982-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2009-08-13 WO disclosed
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS ERBB2, ABL2, TIE1 MEN1 511/4885KMT2A 476/4885MAPK8 563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.